Eli Lilly Signs $1.3 Billion AI-Driven Deal with Superluminal for Obesity Drug Discovery

Eli Lilly's Strategic Move in AI-Driven Drug Discovery

Eli Lilly, a dominant player in the obesity treatment market, has entered into a significant partnership with Superluminal Medicines, a privately held company specializing in AI-driven drug discovery. The deal, valued at $1.3 billion, aims to leverage artificial intelligence to discover and develop small-molecule drugs for treating obesity and other cardiometabolic diseases 1

1

2

Source: BNN

The AI-Powered Platform and GPCR Focus

At the heart of this collaboration is Superluminal's proprietary AI-driven platform, which targets G-protein-coupled receptors (GPCRs). These proteins play a crucial role in various physiological processes, including metabolism, cell growth, and immune responses. The deal grants Lilly exclusive rights to develop and commercialize drug candidates discovered using this platform 3

3

4

Superluminal CEO Cony D'Cruz emphasized the importance of GPCRs, stating, "GPCRs have established themselves as very important targets in the obesity and cardiometabolic landscape, but we're at the very early stages of exploration of the target class" 2

2

Market Dynamics and Competition

The obesity treatment market is projected to reach $150 billion by the next decade, and Lilly is strategically positioning itself to maintain its leadership. This move comes amidst fierce competition, particularly from Danish rival Novo Nordisk, which recently struck a similar $2.2 billion deal with U.S. biotech Septerna to develop small-molecule therapies targeting GPCRs 1

1

3

Lilly has been capitalizing on the popularity of GLP-1 class medicines, including its blockbuster drug Zepbound and Novo's Wegovy. The company is also developing an oral GLP-1 drug, orforglipron, although it has faced challenges in meeting investor expectations 2

2

4

Related Stories

Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development

Eli Lilly Launches $1 Billion AI-Powered Drug Discovery Platform

Eli Lilly Invests $409M in AI-Driven Drug Discovery Partnership with Genetic Leap

Eli Lilly and Nvidia Partner to Build Pharmaceutical Industry's Most Powerful AI Supercomputer for Drug Discovery

Deal Structure and Future Prospects

Under the agreement, Superluminal is set to receive upfront and milestone payments, an equity investment, and tiered royalties on net sales. This structure aligns the interests of both companies in the success of the drug discovery efforts 1

1

2

It's worth noting that Superluminal's lead candidate, which targets the melanocortin 4 receptor for treating rare genetic forms of obesity, is not part of this deal. Human trials for this candidate are expected to begin by the fourth quarter of next year 2

2

4

Source: Benzinga

Broader Industry Trends

This partnership reflects a growing trend in the pharmaceutical industry of leveraging AI and machine learning for drug discovery. It also highlights the increasing focus on developing oral small-molecule drugs for obesity treatment, which could potentially offer advantages over injectable treatments 3

3

4

Superluminal, a Boston-based startup, is backed by notable investors including RA Capital Management, Insight Partners, and NVentures, NVIDIA's venture capital arm, underscoring the growing interest in AI-driven biotech companies 1

1

4